Last update 28 Sep 2024

Diazepam

Overview

Basic Info

SummaryThe pharmacological agent Diazepam, a preeminent GABAA receptor agonist that was granted approval on November 15, 1963, by Waylis, is an efficacious medication used to mitigate a range of conditions, including muscle spasticity, alcohol abstinence, anxiety disorders, and epilepsy. The intricate chemical composition of this pharmacological agent is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. The multifaceted mechanism by which Diazepam operates is by potentiating the effects of gamma-Aminobutyric acid (GABA), an inhibitory neurotransmitter, thereby producing a tranquilizing effect on the body. The pervasiveness of Diazepam within the fields of psychiatry and neurology is incontrovertible, and its usage has become indispensable in the management of a broad spectrum of medical conditions.
Drug Type
Small molecule drug
Synonyms
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, DBF, DBSF
+ [35]
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC16H13ClN2O
InChIKeyAAOVKJBEBIDNHE-UHFFFAOYSA-N
CAS Registry439-14-5

External Link

KEGGWikiATCDrug Bank
D00293Diazepam

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Organophosphate Poisoning
JP
02 Dec 2003
Febrile Seizures Associated With Afebrile Seizures
JP
03 Jul 1992
Seizures
JP
03 Jul 1992
Heart Diseases
CN
01 Jan 1981
Anesthesia
JP
30 Aug 1969
Habit Spasms
JP
30 Aug 1969
Depression
JP
01 Nov 1964
Neurotic Disorders
JP
01 Nov 1964
Alcohol Abstinence
US
15 Nov 1963
Anxiety Disorders
US
15 Nov 1963
Epilepsy
US
15 Nov 1963
Muscle Spasticity
US
15 Nov 1963
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute repetitive seizurePhase 3
US
11 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
50
(Diazepam)
qjalytpmut(jpjajujcbm) = lgeaicaqlw duuvddmwlz (ereflwusru, jkhlhpgjpv - ijijyvahma)
-
03 Sep 2024
Placebo
(Placebo)
qjalytpmut(jpjajujcbm) = jskkokohwg duuvddmwlz (ereflwusru, yicgqtbzzr - ryhvlpyhms)
FDA_CDER
ManualManual
Not Applicable
91
Diazepam Rectal Gel
(First Study)
urcbgmifeq(zqvpqwlots) = pnsdrbznhm hzpcisassm (ofioxjwxmj )
Positive
26 Apr 2024
FDA_CDER
ManualManual
Not Applicable
114
Diazepam Rectal Gel
(Second Study)
infrxlgema(nokptlgqpn) = nxpewdecun lyqgmbkwqr (lchhdwegwj )
Positive
26 Apr 2024
Phase 2
70
(Post-Operative Non Opioid Pain Protocol)
pbjrhmarlg(vthletzhgq) = drwhorpcyb ejzjajhcwq (txsrlomsyb, uaqvcscqxu - xulfwmmlkh)
-
02 Apr 2024
(Post-Operative Traditional Pain Protocol)
pbjrhmarlg(vthletzhgq) = dsuqucnrju ejzjajhcwq (txsrlomsyb, bzjfgllfmy - vaeemdmnzu)
Phase 3
3,225
jnzmbzirqb(dpbeevhkey) = jswpolylzc fvkrwuwcrv (fotanhydvj )
Positive
01 Feb 2024
NEWS
ManualManual
Phase 3
-
diazepam nasal spray
gynqcslelp(lektytolxa) = proportion of patients who achieved resolution of clinically relevant seizures within 10 minutes after administration of a single dose and who remained free from seizures or convulsions for 30 minutes after a single dose bawibktrql (bybdipwacx )
Met
-
18 Oct 2023
Phase 3
CBD
78
No CBD
omdeicicth(sylsomqzot) = tjslnbtxen uuckvfyhyg (fygjmhmexq )
-
01 Oct 2023
Oral-solution CBD
omdeicicth(sylsomqzot) = pyyvadnkqj uuckvfyhyg (fygjmhmexq )
Phase 3
78
aqdetjmlmw(ffnihazhht) = egvaqcjqze hsnxkemepx (jzuerjssyv )
-
01 Oct 2023
Not Applicable
175
ractcevxsk(rgxxvrsznn) = dfshcpzjjz esaxoamwii (jhsincwome )
Positive
04 Sep 2023
Phase 3
175
zrtvudiyew(dkgpzlegla) = ljsxozluwa otsurwohao (dnwiusojrv )
Positive
04 Sep 2023
(5-15 minutes)
zrtvudiyew(dkgpzlegla) = rkxhnyxtme otsurwohao (dnwiusojrv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free